Simvastatin has been shown to reduce portal hypertension through the putative reduction in IHVR by means of several mechanisms, including the induction of KLF2 expression, related to the stimulation of a vasoprotective phenotype in LSECs [11,12,33]. This evidence concerns the gene KLF2 and portal hypertension.